BJDX
Bluejay Diagnostics, Inc.0.9664
-0.0436-4.32%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.75MP/E (TTM)
0.01Basic EPS (TTM)
164.37Dividend Yield
0%Recent Filings
8-K
1-for-4 reverse split effective
Bluejay Diagnostics executed a 1-for-4 reverse stock split, effective January 29, 2026, slashing outstanding shares from 2,834,133 to 708,533. Trading resumes on Nasdaq under BJDX with new CUSIP 095633608; no fractional shares, cash paid instead. Equity awards and warrants adjusted proportionately. Split preserves ownership percentages but hikes per-share price.
8-K
IL-6 antibody production complete
Bluejay Diagnostics completed commercial-scale production of polyclonal and monoclonal IL-6 antibodies on December 29, 2025, meeting internal performance specs for Symphony cartridge manufacturing. Inventory supports over nine million cartridges. Symphony remains in development, pending validation and FDA clearance. No guarantees on timelines.
8-K
Q3 update: trial 50% done
Bluejay Diagnostics reported Q3 results with $3.08 million cash as of September 30, 2025, after $4.5 million October PIPE financing. SYMON-II sepsis trial enrollment hit 50% complete; testing eyes late 2026 finish for 2027 FDA submission, if financed. Amended SanyoSeiko deal bolsters manufacturing. Needs $20 million more by 2027 end. Progress accelerates.
10-Q
Q3 FY2025 results
Bluejay Diagnostics narrowed its Q3 operating loss to $1.6M from $1.4M y/y (derived), driven by higher R&D on clinical trials while trimming other costs; nine-month operating loss improved to $5.5M from $5.7M y/y (derived). Cash burn slowed, with $4.6M used in operations versus $6.4M y/y, ending at $3.1M cash after $3.4M from warrant exercises. No revenue, debt, or FCF as operating cash exceeded capex of zero. October private placement added ~$4.5M gross. SYMON-II trial halfway enrolled. Going concern doubts persist without $20M more funding.
8-K
Bluejay closes $4M net raise
Bluejay Diagnostics closed a $4.5 million private placement on October 10, 2025, selling 175,000 common shares and pre-funded warrants for 2,075,000 shares at $2.00 each, plus Series F warrants for 4,500,000 shares at $1.75 exercisable immediately for 5.5 years. Net proceeds hit $4.0 million after an 8% placement agent fee to Rodman and Renshaw. Cash bolsters FDA approval efforts and working capital, yet dilutes shareholders while locking variable financings for a year.
BDX
Becton, Dickinson and Company
196.39-3.70
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BMRA
Biomerica, Inc.
2.37-0.08
BRKR
Bruker Corporation
44.96-0.71
CODX
Co-Diagnostics, Inc.
0.25-0.02
DGX
Quest Diagnostics Incorporated
178.66-5.45
IDXG
Interpace Biosciences, Inc.
1.14-0.02
LUCD
Lucid Diagnostics Inc.
1.12+0.01
QTRX
Quanterix Corporation
7.36-0.05